Optimization of outcomes related to cytomegalovirus in organ transplant recipients

Transplantation

Volumn 82, Issue 1, 2006, Pages 15-16

  Singh, Nina ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; NOTE; ONSET AGE; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; CYTOMEGALIC INCLUSION BODY DISEASE; GRAFT SURVIVAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MORTALITY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GRAFT SURVIVAL; HUMANS; ORGAN TRANSPLANTATION;

EID: 33747494562     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000228232.09678.6b     Document Type: Note

References (19)

1. Peterson PK, Balfour HH, Jr., Marker SC, et al. Cytomegalovirus disease in renal recipients; a prospective study of the clinical features, risk factors and impact on renal transplantation. Medicine 1980; 59: 283.
2. Akalin E, Bromberg JS, Shegal V, et al. 6 months valganciclovir prophylaxis significantly decreases cytomegalovirus infection incidence in thymoglobulin treated transplant patients. Am J Transplant 2004; 4: 495.
3. Limaye AP, Bakthavatsalam R, Kim HW, et al. Late-onset CMV disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004; 78: 9.
4. Jain A, Orloff M, Lansing K, et al. Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegalovirus (CMV) infection in liver transplant recipients. Am J Transplant 2004; 4(suppl 8): 569.
5. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89.
6. Singh N, Wannstedt C, Keyes L, et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset CMV disease. Transplantation 2005; 79: 85.
7. Singh N, Yu VL. Severing the Gordian Knot of prevention of cytomegalovirus in liver transplant recipients: the principle is the sword. Liver Transplantation 2005; 8: 891.
8. Kletzmayr J, Kotzmann H, Popow-Kraupp T, et al. Impact of high-dose oral acyclovir propohylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996; 7: 325.
9. Balfour HH, Jr., Chace BA, Stapleton JT, et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989; 320: 1381.
10. Gavaldà J, de Otero J, Murio E, et al. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transpl Int 1997; 10: 462.
11. Gane E, Saliba F, Valdecasas GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997; 350: 1729.
12. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplantation 2004; 4: 611-620.
13. Berkman SC, Ashcraft E, Baillie GM, et al. Valganciclovir for CMV prophylaxis in liver transplant recipients: an initial experience. Am J Transplant 2004; 4(suppl 8): 358.
14. Li CR, Greenberg PD, Gilbert MJ, et al. Recovery of HL, A-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971.
15. Scholz D, Arndt R, Meyer R. Evidence for an immunosuppressive activity of ganciclovir. Transplant Proc 1994; 26: 3253.
16. Steininger C, Kundi M, Kletzmayr J, et al. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908.
17. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 10: 1065-1070.
18. Kim DH, Won DI, Lee NY, et al. Survival benefit of asymptomatic cytomegalovirus reactivation after HLA-identical allogeneic peripheral blood stem cell transplantation. Transplantation 2006; 81: 101.
19. Díaz-Pedroche C, Lumbreras C, San Juan R, et al. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82: 30.